GlaxoSmithKline 10 to 50 dollar settlement over Boostrix ads overstating whooping cough transmission

This class action, DeCostanzo v. GlaxoSmithKline, centers on GSK’s “Big Bad Cough” Boostrix ads that ran nationally from 2015–2020 and, plaintiffs allege, overstated the vaccine’s ability to stop vaccinated adults from transmitting pertussis (whooping cough) to others. Boostrix is an FDA‑approved Tdap booster that protects the person vaccinated against tetanus, diphtheria, and pertussis, and the lawsuit does not challenge its safety or efficacy for recipients. The parties agreed to a settlement offering $50 to New York adults (or anyone vaccinated in New York) who can provide proof they received Boostrix between May 20, 2016 and May 20, 2020 and who got the shot specifically to protect someone else, or $10 for claimants without proof; claim forms must be filed by June 8, 2026. GSK denies the allegations and says its ads reflected CDC guidance at the time, and the court did not rule on liability. The suit was filed as a consumer‑protection/false‑advertising claim over marketing versus scientific limits on preventing transmission, and its significance lies in how it may shape pharmaceutical advertising practices and public expectations about indirect vaccine benefits. Regulators and enforcers such as the FDA’s Office of Prescription Drug Promotion and the Federal Trade Commission, along with state consumer‑protection laws, oversee truthfulness in drug promotion, and courts routinely see cases challenging overstated claims by drugmakers—so this settlement fits a broader pattern of litigation prompting companies to sharpen marketing language. For consumers and public‑health communicators, the case underscores the importance of clear messaging about what vaccines protect directly (the recipient) versus what they may or may not prevent in terms of onward transmission.